Sight Sciences Announces Successful Patent Infringement Verdict

Palo Alto – April 26, 2024 – Cooley represented Sight Sciences (listed as SGHT on Nasdaq), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, which received a jury trial win on April 26, 2024, against its competitors – Alcon, Alcon Vision and Alcon Research (collectively known as Alcon) and Ivantis – in the US District Court for the District of Delaware. Attorneys Michelle Rhyu, Orion Armon, Jeff Karr and Eamonn Gardner led the Cooley trial team.

Sight Sciences claimed that Alcon’s and Ivantis’ sale of the Hydrus Microstent infringed three key patents covering medical devices that are implanted into the eye to treat mild to moderate open-angle glaucoma.  The patents were prosecuted by Cooley partner Mika Mayer and her team. Glaucoma is a common eye disease that affects tens of millions of people worldwide and is the leading cause of irreversible blindness.

The jury found that Alcon’s and Ivantis’s sale of the infringing Hydrus Microstent caused Sight Sciences to lose sales of its OMNI Surgical System device and awarded lost profits damages of $5.5 million and royalty damages of $28.5 million – totaling $34 million. When enhancements for willfulness and future damages are factored in, Alcon’s and Ivantis’s total liability is expected to increase.

The patents at issue are US Patent Nos. 8,287,482, 9,370,443 and 11,389,328.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.